ClinicalTrials.gg
Not yet recruitingNCT07297875Updated Dec 22, 2025

A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia

A Phase 1/2 interventional study of ABSK061 in Achondroplasia, sponsored by Abbisko Therapeutics Co, Ltd. Not yet recruiting at 7 sites in China. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
3 Years to 12 Years
Sex
All
01

Study summary

This is a multicenter, non-randomized, open-label, phase I/II study in children with ACH. This study will start with a dose escalation of ABSK061 in children with ACH to evaluate the safety, tolerability, PK, and efficacy. The RDE confirmation part will evaluate the safety and efficacy of ABSK061 at the recommended doses for expansion (RDEs) in children with ACH. All patients enrolled in the dose escalation part and RDE confirmation part can enter the extended treatment period to further evaluate the long-term safety, tolerability, and long-term efficacy of ABSK061 in children with ACH.

Read the detailed description

Up to 50 children aged 6 to \< 12 years (inclusive of 6 years) with ACH and up to 30 children aged 3 to \< 6 years (inclusive of 3 years) with ACH are expected to be enrolled in the dose escalation part of the study; up to 30 children aged 3 to \< 12 years (inclusive of 3 years) with ACH are expected to be enrolled in the RDE confirmation part.

Children enrolled in this study will be required to complete at least 6 months and up to 2 years of growth assessment and observation of natural history of ACH in the sponsor's observational study (ABSK061-001).

Dose Escalation Part All patients enrolled in the dose escalation part will continue to receive ABSK061 once daily (QD) dosing frequency and will enter the extended treatment period for 52 weeks after completing 26 weeks of treatment.

The dose escalation includes a total of 5 potential dose levels starting at an initial dose of 0.064 mg/kg QD. In the absence of DLTs or ≥ grade 2 drug-related adverse events, the initial maximum permitted dose increment will not exceed 200%. In the presence of a DLT or ≥ grade 2 drug-related adverse event, dose escalation for subsequent cohorts will follow a modified Fibonacci scheme, in which the first two consecutive dose cohorts will each receive a maximum dose increase of up to 67% and 50%, respectively, and the remaining dose cohorts will receive a maximum of 33% increase. The potential dose levels to be explored are listed in the table below. Based on cumulative safety, PK/PD, efficacy data, other potential dose levels not listed may also be explored in this study following the dose escalation rules.

Dose escalation part will be divided into Part A and Part B according to patient age, with Part A enrolling children with ACH aged 6 to \< 12 years (inclusive of 6 years) and Part B enrolling children with ACH aged 3 to \< 6 years (inclusive of 3 years). In this study, two sentinel patients will be set for both parts of each dose level, thereby the interval for the first dose between the first 2 patients and the third patient is not less than 28 days.

RDE Confirmation Part In this part, up to 30 children aged 3 to \< 12 years (inclusive of age 3) with ACH will be enrolled to receive one or two RDEs. The RDEs will be selected from the safe doses determined in the dose escalation to further evaluate the safety and efficacy of ABSK061 in children with ACH. Patients in this part will not be included in the DLT evaluable population. Dose decisions for RDE Confirmation Part will be based on discussion and alignment between the sponsor and investigators. Safety, PK/PD, and efficacy data will be monitored and assessed in real time during the study. The study may be discontinued early if any safety risk to the patients are identified, upon agreement between the investigators and sponsor.

Extended Treatment Period After completing 26 weeks of treatment with ABSK061 in the dose escalation part and RDE confirmation part, children with ACH will enter the extended treatment period for 52 weeks to further assess the long-term safety, tolerability and efficacy. In extended treatment period, patients will be treated at the dose assigned for dose escalation (intra-patient dose escalations are allowed for patients at low dose levels in Part A). Dose will be calculated based on body weight and may be adjusted due to weight change at the Week 27 (W27D1, i.e., just entering the extended treatment period), Week 41 (W41D1), Week 53 (W53D1), and Week 67 (W67D1) visits.

After completing 78 weeks of study treatment set in the protocol, all patients in this study can be enrolled into a separate long-term extension study conducted by the sponsor to continue ABSK061 treatment. This is to further assess the long-term safety and efficacy of ABSK061 in children with ACH. If the investigator determines that a patient is no longer eligible to continue in the long-term extension study due to safety concerns or lack of clinical benefit, treatment with ABSK061 will be discontinued.

02

Conditions studied

  • Achondroplasia

Browse trials for

03

In context

Achondroplasia

47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.

This study's planned enrollment of 110 is above the median of 74 across 28 interventional studies indexed under Achondroplasia.

Browse Achondroplasia studies →

Lead sponsor

Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Prior to screening, the guardians and children with ACH (if applicable) must voluntarily provide signed .
  2. Patients with a clear clinical diagnosis of ACH confirmed by genetic testing for an FGFR3 mutation.
  3. Male or female, age at screening:

    Dose Escalation Part A: 6 to \< 12 years (inclusive 6 years) Dose Escalation Part B: 3 to \< 6 years (inclusive 3 years) RDE Confirmation Part: 3 to \< 12 years (inclusive 3 years).

  4. Have completed at least 6 months (i.e., the "Day 181" visit) of growth assessment and observation of natural history of ACH in the observational study (ABSK061-001) before study entry.
  5. Tanner Stage 1 breast development for females or Tanner Stage 1 external genitalia development for males at screening

Exclusion criteria

Exclusion Criteria:

  1. Known allergy or to any component of the study drug.
  2. Bone age ≥ 14 years as assessed by the investigator based on hand and wrist X-ray.
  3. Have a form of skeletal dysplasia other than ACH or known medical conditions that result in short stature or abnormal growth, including but not limited to severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Turner syndrome, pseudoachondroplasia, inflammatory bowel disease, chronic renal insufficiency, active celiac disease a, Vitamin D deficiency b, untreated hypothyroidism c, poorly controlled diabetes ( ≥8.0%) or diabetic complications
  4. History or presence of injury or disease of the growth plate(s), other than ACH, that affects growth potential of long bones.
  5. AGV ≤ 1.5 cm/year over at least 6 months (i.e., must have completed the 'Day 181' visit) in the observational study (ABSK061-001), or current evidence of growth plate closure (proximal tibia, distal femur).
  6. Current epiphyseal injury (Salter-Harris fracture) or severe hip pain.
  7. For ACH-related complications: current severe sleep apnea, symptomatic and/or requiring intervention for hydrocephalus, or spinal cord compression at the cranio-cervical junction, or prior ventriculoperitoneal shunt surgery.
  8. Have received any dose of medications affecting stature or body proportionality, such as human growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic steroids within 12 months prior to screening.
  9. Prior treatment with any CNP analogues or FGFR inhibitors. Prior use of any drugs or investigational medical devices that affect height or body proportion.
  10. History of any prior bone-related surgery that affects long bone growth, such as orthopaedic reconstructive surgery, limb lengthening, or osteotomy (patients who have previously undergone foramen magnum decompression or intervertebral disc/laminectomy are allowed if they have fully recovered after surgery and bone healing has occurred for at least 6 months. Patients who have previously undergone eight-plate epiphysiodesis are allowed if the plate has been removed and healed for at least 4 weeks).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    ABSK061

    Dose escalation part will be divided into Part A and Part B according to patient age, with Part A enrolling children with ACH aged 6 to \< 12 years (inclusive of 6 years) and Part B enrolling children with ACH aged 3 to \< 6 years (inclusive of 3 years). In this study, two sentinel patients will be set for both parts of each dose level, thereby the interval for the first dose between the first 2 patients and the third patient is not less than 28 days. This study will employ the Bayesian optimal interval (BOIN) design for dose escalation part to guide dose escalation. The target toxicity rate for the MTD is φ = 0.25 and the maximum sample size for the dose escalation part will be 80 (50 in Part A and 30 in Part B). The DLT observation period is defined as the first 28 days after administration of ABSK061. After the RDE is confirmed in the dose Escalation part, the dose Expansion phase will be conducted.

    Drug: ABSK061

Interventions

  • ABSK061 is supplied as minitablets filled in capsules. Four strengths of capsules will be provided: 0.2 mg, 2 mg, 3 mg, and 5 mg. Each patient can only be administered with a single strength. All patients will be administered orally once daily under the fasted state, i.e., fast from 2 hours before dosing to 1 hour after dosing. Dose will be calculated based on the patient's weight, and detailed rules for dose calculation are provided. Take out the ABSK061 capsule containing minitablets, take off the capsule cap and decant the content (minitablets), swallow the minitablets completely with water without chewing (the recommended water volume is 50-180 mL). If there is difficulty swallowing all the minitablets at once, they may be taken in several portions as needed, but the entire dose should be taken within 10 minutes. If needed, yogurt or apple sauce can be used as vehicles to facilitate swallowing of the minitablets.

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs)

    Incidence of dose-limiting toxicities (DLTs) in the DLT observation period, defined as Day 1 to Day 28 of dosing

    Time frame: Day 1 to Day 28 of dosing

  2. Incidence and severity of adverse events (AEs)

    Incidence and severity of adverse events (AEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) using Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0), and relatedness, rate of dose modifications (including dose interruption and dose reduction) or discontinuation of study drug due to toxicity, and changes from baseline in safety assessments such as laboratory parameters, x-ray, electrocardiograms (ECGs), echocardiograms, vital signs, and physical examinations (including ophthalmic examinations)

    Time frame: up to 87 weeks

  3. Changes from baseline in the Annualized Growth Velocity (AGV, cm/year)

    Changes from baseline in the Annualized Growth Velocity (AGV, cm/year) over 52 weeks \[baseline is defined as the AGV obtained through at least 6 months of observation in the observational study (ABSK061-001)\]

    Time frame: Day 1 of dosing to 78-week End of Treatment

Secondary outcomes

  1. Cmax

    maximum observed concentration

    Time frame: Day 1 of dosing to 78-week End of Treatment

  2. Tmax

    time to maximum observed concentration

    Time frame: Day 1 of dosing to 78-week End of Treatment

  3. AUC

    area under the concentration-time curve

    Time frame: Day 1 of dosing to 78-week End of Treatment

  4. t1/2

    half-life

    Time frame: Day 1 of dosing to 78-week End of Treatment

  5. Vz/F

    apparent volume of distribution

    Time frame: Day 1 of dosing to 78-week End of Treatment

  6. CL/F

    apparent oral clearance

    Time frame: Day 1 of dosing to 78-week End of Treatment

  7. Cmax,ss

    maximum observed concentration of steady/state

    Time frame: Day 1 of dosing to 78-week End of Treatment

  8. Cmin,ss

    minimum observed concentration of steady/state

    Time frame: Day 1 of dosing to 78-week End of Treatment

  9. AUCtau,ss

    area under the concentration-time curve after multiple dose

    Time frame: Day 1 of dosing to 78-week End of Treatment

  10. AR

    accumulation ratio

    Time frame: Day 1 of dosing to 78-week End of Treatment

  11. standing height

    calculated to the nearest 0.1 cm

    Time frame: Day 1 of dosing to 78-week End of Treatment

  12. sitting height

    calculated to the nearest 0.1 cm

    Time frame: Day 1 of dosing to 78-week End of Treatment

  13. sitting height to standing height ratio

    This parameter is calculated as the ratio of sitting height to total standing height. It is used to assess the abnormality in body proportions, specifically the relative trunk-to-lower limb length. In patients with achondroplasia, this ratio is typically increased. Within the clinical trial, this measure is used to evaluate the treatment drug's effect on body proportions.

    Time frame: Day 1 of dosing to 78-week End of Treatment

  14. height Z scores

    This measure is defined as the number of standard deviation units by which the subject's height differs from the mean height of a healthy, age- and sex-matched reference population. It is a standardized value used to precisely quantify the degree of deviation from the normal growth curve. In the clinical trial, it serves as a key parameter for assessing the treatment's efficacy in improving linear height growth.

    Time frame: Day 1 of dosing to 78-week End of Treatment

Other outcomes

  1. Range of Motion (ROM)

    Mean change from baseline in ROM of the affected joint

    Time frame: Day 1 of dosing to 78-week End of Treatment

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2028, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 22, 2025
StartEst.
Dec 10, 2025
Primary completionEst.
Dec 15, 2028
CompletionEst.
Mar 15, 2031
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07297875
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
Dec 10, 2025 (estimated)
Primary completion
Dec 15, 2028 (estimated)
Completion
Mar 15, 2031 (estimated)
Last update
Dec 22, 2025

Study contacts

Jing Zhang
Contact
jing.zhang@abbisko.com
+86-15002126439
Shuqi Zeng
study director · 12B, Building 1, No 515, Huanke Road, Pudong New Area, Shanghai 201210, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABSK061

Start the discussion